Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Where is everyone?

<< Previous

Bullboard Posts

Next >>

Comment by PTBaileyon Feb 07, 2022 1:24pm

94 Views

Post# 34405457

RE:Where is everyone?

Mrs Bailey was my mother.

My thinking is pretty much same as everyone else, waiting for some positive news on phase one, no idea what the hold up is.

So I am disappointed and frustrated with the delay. We are still in the process and trying to meet the requirements of Sentica, which at this point makes me think it must be a confusing and complex one, or else they keep changing the goal posts.

It isn't making much sense to me at this point but still holding my shares.

Basically I am in the dark.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario